Traditional Chinese medicine (TCM) manufacturer Guizhentang's plan to get listed in the New Third Board has failed again, three years after it withdrew its IPO application in 2012. Both times, the company had to forego funding following a public backlash over its practice of extracting bear bile - its main product. Full Story